Matrix metalloproteinases in human melanoma

被引:354
作者
Hofmann, UB
Westphal, JR
van Muijen, GNP
Ruiter, DJ
机构
[1] Univ Wurzburg, Dept Dermatol, D-8700 Wurzburg, Germany
[2] Univ Hosp, Dept Pathol, Nijmegen, Netherlands
关键词
adhesion molecules; matrix metalloproteinases; melanoma; tissue inhibitor of matrix metalloproteinases; tumor progression;
D O I
10.1046/j.1523-1747.2000.00068.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Cutaneous melanoma is a highly invasive and metastatic tumor. Degradation of basement membranes and extracellular matrix is an essential step in melanoma cell migration, invasion, and metastasis formation. Matrix metalloproteinases and their tissue inhibitors play a crucial role in these complex multistep processes. Melanoma cells may express a number of matrix metalloproteinase family members (MMP-1, MMP-2, MMP-9, MMP-13, and MT1-MMP) as well as their tissue inhibitors (TIMP-1, TIMP-2, and TIMP-3). Numerous studies have examined matrix metalloproteinases, their tissue inhibitors, and the molecules that regulate their expression and/or activation in melanoma cell lines in vitro and in vivo, and in human melanocytic lesions. Recent results have indicated that adhesion molecutes such as CD44 and integrin alpha(v)beta(3) are involved in positioning activated matrix metalloproteinase molecules on the cell surface of invasive tumor cells. In this review we evaluate these novel aspects of the role of matrix metalloproteinases and their tissue inhibitors in melanoma progression. We conclude that the balance between levels of activated matrix metalloproteinases and expression levels of their tissue inhibitors, and the coexpression of activated matrix metalloproteinases and adhesion molecules are important factors in determining melanoma cell invasion, tumor growth, and metastasis formation.
引用
收藏
页码:337 / 344
页数:8
相关论文
共 98 条
  • [81] Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO
  • [82] 2-T
  • [83] Thewes M, 1999, CLIN EXP DERMATOL, V24, P122
  • [84] Ueno H, 1997, CANCER RES, V57, P2055
  • [85] Vaisanen A, 1996, J PATHOL, V180, P283
  • [86] Väisänen A, 1998, J PATHOL, V186, P51
  • [87] Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO
  • [88] 2-B
  • [89] vandenOord JJ, 1997, AM J PATHOL, V151, P665
  • [90] Wagner S N, 1992, Diagn Mol Pathol, V1, P200, DOI 10.1097/00019606-199209000-00007